Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Breast Care (Basel, Switzerland)|July 12, 2021
Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the GuidelinesMichael P Lux, Sonja Wasner, Julia Meyer, et al.
Breast Care (Basel, Switzerland)|July 12, 2021
Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyMarius Wunderle, Lothar Häberle, Alexander Hein, et al.
Scientific Reports|September 26, 2020
HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatmentFranziska M Wuerfel, Hanna Huebner, Lothar Häberle, et al.
Geburtshilfe Und Frauenheilkunde|January 5, 2024
RANK and RANKL Expression in Tumors of Patients with Early Breast CancerAnnika Behrens, Lena Wurmthaler, Felix Heindl, et al.
Cancers|November 13, 2021
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular SubtypesRamona Erber, Sareetha Kailayangiri, Hanna Huebner, et al.
Breast (Edinburgh, Scotland)|June 22, 2021
Mammographic density and prognosis in primary breast cancer patientsFelix Heindl, Peter A Fasching, Alexander Hein, et al.
JMIR Cancer|August 9, 2017
Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer PatientsAndreas D Hartkopf, Joachim Graf, Elisabeth Simoes, et al.
Archives of Gynecology and Obstetrics|June 5, 2024
Correlation of RANK and RANKL with mammographic density in primary breast cancer patientsMarius Wunderle, Felix Heindl, Annika S Behrens, et al.
BMC Cancer|February 22, 2018
Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patientsHanna Huebner, Peter A Fasching, Walter Gumbrecht, et al.
Gynecologic Oncology|March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancerPaul Gass, Falk C Thiel, Lothar Häberle, et al.
Pageof 8